Protocol liver biopsy is the only examination that can detect mid-term graft fibrosis after pediatric liver transplantation

Table 6 Clinical and histopathological findings of cases who performed protocol liver biopsy at both two and five years after living donor liver transplantation

Case	Original disease	Age at LT/sex	Previous ACR	Post-transplant complications	IS at two years PLB	Tac trough at PLB	ALT/HA at PLB	A/F at PLB	IS at five years PLB	Tac trough at PLB	ALT/HA at PLB	A/F at PLB
1	OTCD	46/female	-	-	Tac (3.0)	2.5	12/35	2/1	Tac (1.0)/MMF (400)	0.5	11/52	1/1
11	BA	26/male	+	PVS	Tac (0.8)/MP (4.0)/MMF (500)	3.2	20/11	0/1	Tac (1.6)/MP (4.0)/MMF (1500)	2.2	12/17	2/2
12	BA	114/male	-	BDS	Tac (2.0)	2.6	14/21	1/0	Tac (3.0)	2.3	16/20	1/2
13	BA	10/female	+	CMV-I	Tac (0.4)	3.8	19/11	0/0	Tac (1.6)	2.8	18/< 9	1/2
14	BA	30/male	-	HVS	Tac (1.2)	5.3	18/29	1/1	Tac (2.0)/MP (1.0)/MMF (1000)	5.6	12/23	1/2
15	BA	120/female	-	BDS	Tac (1.5)/PSL (2.5)	4.4	15/14	0/0	Tac (4.0)	7.0	17/< 9	0/0
16	BA	163/male M	+	BDS/CMV-I	CsA (150)	CsA 50	9/27	0/0	CsA (150)/MMF (1000)	CsA 83	91020	0/1
17	BA	8/female	+/OKT3	PVS/CMV-I	Tac (0.8)/MP (0.5)	2.4	30/36	0/0	Tac (2.0)	5.3	15/18	1/1
18	BA	12/male	+	-	Tac (0.8)	3.8	14/58	0/0	Tac (0.8)	0.2	8/20	1/1
19	BA	13/female	+	CMV-I	Tac (1.6)/MP (2.0)	9.3	22/11	0/0	Tac (1.4)/MP (3.0)/MMF (500)	2.1	15/15	0/1
20	AD	19/female	+	CMV-I	Tac (0.8)/MMF (500)	2.3	19/13	0/1	Tac (2.4)/MMF (500)	3.8	14/15	1/1
21	WD	112/male	-	-	Tac (4.0)	1.3	16/16	0/0	Tac (5.0)	1.4	19/13	0/0
22	BA	170/female	+	BDS	Tac (2.0)	6.3	17/16	0/1	Tac (6.0)/MP (12)/MMF (2000)	15.5	39/22	1/0
23	BA	33/F	+	HVS	Tac (1.0)/MP (2.0)/MMF (400)	3.7	10/< 9	0/0	Tac (1.5)/MMF (1000)	5.4	41/19	1/0
24	BA	9/female	-	HAT	Tac (0.6)	0.3	14/24	0/0	Tac (0.8)	0	10/10	0/0
25	BA	28/female	-	-	Tac (0.4)	2.8	18/< 9	0/0	Tac (1.0)	0.9	15/10	1/0
26	BA	9/female	-	IHBDS	Tac (0.4)	2.1	23/< 9	0/1	Tac (2.0)/MP (0.5)/MMF (500)	5.3	41/19	1/1
27	AD	19/male	-	-	Tac (0.6)	3.3	12/17	0/0	Tac (2.0)/MMF (500)	1.5	11/59	0/0
28	BA	45/female	-	BDS	Tac (1.2)	3.6	13/15	0/0	Tac (1.5)	4.6	11/10	0/0
29	BA	9/female	-	-	Tac (0.4)	0.9	11/17	0/0	Tac (0.8)	1.1	13/25	0/0
30	CEPS	37/male	-	-	Tac (2.0)/MP (2.5)/MMF (500)	2.5	13/< 9	0/0	Tac (2.0)/MP (1.5)/MMF (500)	3.9	11/< 9	0/0

PLB: Protocol liver biopsy; LDLT: Living donor liver transplantation; ACR: Acute cellular rejection; IS: Immunosuppressants; Tac: Tacrolimus; ALT: Alanine amino transferase; HA: Hyaluronic acid; A: Activity; F: Fibrosis; OTCD: Ornithine transcarbamylase deficiency; BA: Biliary atresia; AD: Alagille syndrome; WD: Wilson disease; CEPS: Congenital extrahepatic portsystemic shunt; OKT3: Muromonab-CD3; PVS: Portal vein stenosis; BDS: Biliary duct anastomotic stenosis; CMV-I: Cytomegalovirus infection; HVS: Hepatic vein stenosis; HAT: Hepatic artery thrombosis; IHBDS: Intrahepatic biliary duct stenosis; MP: Methylprednisolone; MMF: Mycophenolate mofetil; PSL: Prednisolone; CsA: Cyclosporin A.